TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10826459
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 10 days
Study: 2053097
Drug: Psoas compartment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoas compartment block with additional inhalation anaesthesia
Study: 17971587
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and RT during induction (up-front RT)
Study: 15368110
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (10 mg daily)
Study: 15100671
Drug: Levocetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5 mg)
Study: 9519853
Drug: SAIB (sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAIB (sucrose acetate isobutyrate) ingestion at a dose of 20 mg/kg body weight for 14 days
Study: 2801555
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (placebo group)
Study: 2801555
Drug: Proximal left
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal left anterior descending coronary artery affected (Anticoagulant therapy)
Study: 822858
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) injection
Study: 822858
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid injection
Study: 31604146
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate supplementation (beetroot-based high-nitrate supplement)
Study: 29137842
Drug: Cetrozole (1.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrozole (1.98 μg)
Study: 29137842
Drug: TMD-322 (1.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMD-322 (1.98 μg)
Study: 29137842
Drug: Anastrozole (1.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1.98 μg)
Study: 22672214
Drug: Liquid paraffin
Normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid paraffin plus antiseptic cream
Study: 23219861
Drug: Pimozide augmentation
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide augmentation
Study: 21642511
Drug: Low-dose PSW
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PSW treatment (power of 14.5 W, treatment duration of 19 minutes, total energy of 17 kJ)
Study: 21642511
Drug: High-dose PSW
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PSW treatment (power of 14.5 W, treatment duration of 38 minutes, total energy of 33 kJ)
Study: 18804555
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg q.d.)
Study: 17303443
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (capacitively coupled, pulsed electrical stimulation device)
Study: 11236229
Drug: Combination gel
Normalized name: SUNSCREEN-30 PABA-FREE COMBINATION GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination gel (5% benzoyl peroxide and 1% clindamycin)
Study: 2511136
Drug: vasopressin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: vasopressin (0.4 to 0.8 unit per min for 12 hr) associated with transdermal nitroglycerin (10 mg in 24 hr)
Study: 1015360
Drug: Sulfaisomidine administered
Normalized name: sulfisomidine
DrugBank: Sulfaisodimidine (DB13283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfaisomidine administered on an empty stomach
Study: 1015360
Drug: Sulfaisomidine administered
Normalized name: sulfisomidine
DrugBank: Sulfaisodimidine (DB13283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfaisomidine administered with a standardized breakfast
Study: 31519301
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% cream (CPS)
Study: 31519301
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (PLA)
Study: 26658524
Drug: Task-oriented exercise
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented exercise with mirror therapy (EG)
Study: 24447460
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) delivered by highly trained professional therapists
Study: 24447460
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) and Cognitive Behaviour Therapy (CBT)
Study: 21058475
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection therapy with compound Danshen injection at Zusanli (ST 36) and Weishu (BL 21) for 2 weeks
Study: 21058475
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Omeprazole for 2 weeks
Study: 15637764
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Fuzheng Yiliu decoction
Study: 10454403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a standard smoking cessation programme with nicotine gum and a behavioural weight control programme including a very low energy diet
Study: 8580269
Drug: GR122311X 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 200 mg b.d.
Study: 8580269
Drug: GR122311X 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 400 mg b.d.
Study: 8580269
Drug: GR122311X 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR122311X 800 mg b.d.
Study: 8580269
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 150 mg b.d.
Study: 2790864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zinc citrate (14.4 mM) and SLS (34.7 mM)
Study: 31556633
Drug: Schema mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema mindfulness-based cognitive therapy (SMBCT) + treatment as usual (TAU)
Study: 31556633
Drug: Competitive memory
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Competitive memory therapy (COMET) + treatment as usual (TAU)
Study: 31171755
Drug: Eculizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (monoclonal antibody against complement C5)
Study: 28147351
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (balloon dilatation and stenting)
Study: 21288340
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention including a depression awareness and physical activity training session for care home staff, plus a whole home physical activation programme with twice weekly physiotherapist-led exercise groups for 12 months.
Study: 18165589
Drug: Nicotine 3
Normalized name: Nicotine 312.5 microgram/hour prolonged-release transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 3 mg
Study: 12646431
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of contrast material plus a 50‐mL saline chaser
Study: 12646431
Drug: 150 mL
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL of contrast material
Study: 9350881
Drug: Plantain flour‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantain flour‐based solution (Group B)
Study: 8411742
Drug: Propranolol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (dose reducing heart rate by 25%)
Study: 8411742
Drug: Sclerotherapy (intra‐variceal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (intra‐variceal and extra‐variceal injection of ethanolamine oleate)
Study: 25748876
Drug: Direct referral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct referral to low-dose chest CT (LDCT)
Study: 18637080
Drug: IV butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV butorphanol (1 mg)
Study: 22411639
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac (30 mg)
Study: 11739221
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review by a pharmacist
Study: 12969084
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg administered through a nasogastric tube
Study: 12969084
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg administered orally as an intact capsule
Study: 8884304
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day for 7 days, Tinidazole 500 mg bid for 7 days, Clarithromycin 250 mg bid for 7 days (Group A)
Study: 8884304
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for 14 days, Amoxycillin 1000 mg bid for 14 days (Group B)
Study: 4001769
Drug: Mebendazole 2
Normalized name: mebendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 2 G per day for 14 days preceded by 300 mg of levamisole in 2 doses
Study: 4001769
Drug: Placebo vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vitamin tablets for 14 days
Study: 29614378
Drug: Exposure-based internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based internet-delivered cognitive behavior therapy (Internet-CBT)
Study: 29303212
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel
Study: 20657532
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin spray (added to antiplatelet therapy)
Study: 20657532
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy only
Study: 11126694
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol patch
Study: 9091475
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (IFN‐gamma) 100 micrograms subcutaneously for 5 consecutive days followed by 100 micrograms once weekly for 4 weeks
Study: 7690364
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 300 mg im, each week for 6 weeks
Study: 7690364
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 300 mg im, each week for 6 weeks
Study: 30324422
Drug: Phase III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III formulation with reduced SLS content, administered following a low-fat meal
Study: 30324422
Drug: Phase I/II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I/II formulation, administered under the same conditions
Study: 26684776
Drug: Traditional sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional sequential electrode implantation
Study: 22237795
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural coping skills (CBCS); specific dosage and duration not mentioned.
Study: 18343253
Drug: Topical amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amethocaine gel 4%
Study: 15809408
Drug: Medications (paroxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications (paroxetine, up to 50 mg daily)
Study: 8706447
Drug: MAK 195F
Normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAK 195F (anti-TNF antibody) at 0.1 mg/kg
Study: 8706447
Drug: MAK 195F
Normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAK 195F (anti-TNF antibody) at 0.3 mg/kg
Study: 8706447
Drug: MAK 195F
Normalized name: MAK-683
DrugBank: MAK-683 (DB19205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAK 195F (anti-TNF antibody) at 1.0 mg/kg
Study: 2183879
Drug: Diazepam 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.12 mg/kg
Study: 20348487
Drug: Subantimicrobial-dose-doxycycline (SDD)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subantimicrobial-dose-doxycycline (SDD)
Study: 2915293
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg IVIG (Gamimune)
Study: 30797491
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EBUS‐GS and virtual bronchoscopic navigation (VBN)
Study: 21526380
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (with hypointensity on MRI, n = 19)
Study: 9121638
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) using 'Elektronika‐2M' apparatus with a current of 45 microA for 10‐20 min, with courses consisting of 10‐12 treatments.
Study: 9121638
Drug: Standard methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methods of treatment (novocaine blockade, analgesics, etc.)
Study: 29329493
Drug: Meloxicam IV
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam IV 60 mg
Study: 29329493
Drug: Meloxicam IV
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam IV 15 mg
Study: 24825642
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg daily)
Study: 24763888
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with hyperbaric bupivacaine (2 ml, 0.5%)
Study: 24763888
Drug: L1 paravertebral
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L1 paravertebral block combined with psoas compartment block and sciatic nerve block with bupivacaine hydrochloride (total 35 ml)
Study: 22838231
Drug: self‐etch adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐etch adhesive (Prompt L Pop)
Study: 22838231
Drug: no surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: no surface treatment (negative control)
Study: 19025303
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication therapy (10-day course of rabeprazole, amoxicillin, and clarithromycin, followed by 20 mg of rabeprazole for 3 months)
Study: 19025303
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (20 mg of rabeprazole for 3 months)
Study: 16861942
Drug: Steroid stop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid stop
Study: 15636615
Drug: Control (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (triple therapy)
Study: 14651431
Drug: MOS-HIV health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOS-HIV health survey administered at baseline and every 3 months during 1-year follow-up
Study: 10965646
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with no additional problem solving
Study: 28510646
Drug: Switched DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched DAPT (aspirin plus clopidogrel)
Study: 28510646
Drug: Unchanged DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged DAPT (aspirin plus newer P2Y12 blocker)
Study: 25728888
Drug: L. reuteri-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri-containing lozenges
Study: 23222534
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) - 15 mg/kg to a maximum of 1000 mg IV for NDD-CKD; 200 mg IV push for HD-CKD
Study: 23222534
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care (SMC) - treatment determined by the investigator, could include oral iron, IV iron or no iron
Study: 7918139
Drug: Simendan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan 1.0 mg
Study: 7918139
Drug: Simendan 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan 2.0 mg
Study: 7918139
Drug: Simendan 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan 5.0 mg
Study: 7918139
Drug: Simendan 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simendan 10.0 mg
Study: 3451888
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg falipamil
Study: 3451888
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of atropine
Study: 3451888
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cumulative dose of atropine
Study: 3451888
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg falipamil
Study: 3451888
Drug: ULFS 49
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULFS 49 Cl (3 different oral doses)
Study: 3451888
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 2.5 mg p.o. (minimal effective dose)
Study: 3451888
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 5 mg p.o. (therapeutic dose)
Study: 3451888
Drug: Side-effects typical
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side-effects typical for 'specific bradycardic agents'
Study: 29374674
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message intervention providing information, motivation, and support for medication adherence, smoking cessation, healthy diet, and exercise.
Study: 28376651
Drug: brinzolamide 1.0%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC)
Study: 23232154
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, max 600 mg) and Codeine (1 mg/kg, max 60 mg)
Study: 23232154
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, max 600 mg) and Placebo
Study: 16155274
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn/d
Study: 10702174
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Fe/d
Study: 10702174
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn/d plus 20 mg Fe/d
Study: 8404191
Drug: SHRZ/HR regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHRZ/HR regimen (2 months of daily streptomycin, isoniazid, rifampin, and pyrazinamide followed by 4 months of isoniazid plus rifampin)
Study: 8404191
Drug: SHZ Cipro/H
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHZ Cipro/H Cipro regimen (2 months of daily streptomycin, isoniazid, pyrazinamide, and ciprofloxacin followed by 4 months of isoniazid plus ciprofloxacin)
Study: 27793237
Drug: Sufentanil in
Normalized name: sufentanil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil in combination with low-dose hyperbaric bupivacaine
Study: 16860169
Drug: ASA 325
Normalized name: ASA 325 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 325 mg/d for 1 week, followed by ASA 100 mg/d plus clopidogrel 300 mg loading dose followed by 100 mg/d for 36 weeks (ASA+Clop group)
Study: 16860169
Drug: ASA alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA alone (325 mg/d for 1 week, followed by 75 mg/d for 36 weeks) (ASA group)
Study: 12623974
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day, given 8 hours after awakening (time 2)
Study: 12623974
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day, given before bedtime (time 3)
Study: 8408538
Drug: Counselling intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counselling intervention (three sessions of counselling before, during, and after the first treatment cycle)
Study: 8408538
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (information about the treatment programme only)
Study: 3547370
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (Control)
Study: 31219517
Drug: mECX+L (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: mECX+L (modified ECX plus lapatinib)
Study: 28968877
Drug: School-based and
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based and village-wide preventive chemotherapy strategies (MDA) for Schistosoma mansoni
Study: 24448262
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA)
Study: 23405376
Drug: Self-administered testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered testing using the Gen-Probe APTIMA Combo 2 (AC2) kit
Study: 19706084
Drug: 1.2% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% clindamycin and 0.025% tretinoin (CLIN/RA) gel
Study: 16730066
Drug: 5‐mg intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg intralesional injection of 5‐FU weekly for 2 weeks
Study: 16730066
Drug: 20‐mg intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg intralesional injection of triamcinolone